z-logo
Premium
The Fruits of Cudrania tricuspidata Suppress Development of Atopic Dermatitis in NC/Nga Mice
Author(s) -
Lee Hoyoung,
Ha Hyekyung,
Lee Jun Kyung,
Seo Changseob,
Lee Namhun,
Jung DaYoung,
Park SangJoon,
Shin Hyeun Kyoo
Publication year - 2012
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.3577
Subject(s) - histamine , atopic dermatitis , immunoglobulin e , dermis , medicine , allergy , immunology , atopy , chemokine , pharmacology , antibody , inflammation , pathology
The fruits of Cudrania tricuspidata are a medicinal herb in Korea, known for its antiatherosclerotic and antiinflammatory effects. Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by the influx of lymphocytes into the dermis. Using an animal model of AD, we assessed whether C. tricuspidata suppresses the development of AD‐like skin lesions. Cudrania tricuspidata was administered orally to NC/Nga mice with Dermatophagoides‐farinae ‐induced AD‐like lesions for 49 days. The effects of C. tricuspidata were assessed by measuring clinical symptoms, swelling of the skin on the back and ears, and plasma concentrations of mTARC (mouse thymus and activation regulated chemokine), histamine and immunoglobulin E (IgE). We found that C. tricuspidata (60 mg/kg/day) inhibited the development of AD‐like skin lesions, reduced skin dermatitis scores and inhibited the histological changes induced by repeated application of D. farinae . In addition, C. tricuspidata inhibited the increases in plasma concentrations of mTARC, histamine and IgE induced by D. farinae . These findings indicate that C. tricuspidata inhibits the development of AD‐like skin lesions induced by repeated applications of D. farinae in sensitized NC/Nga by suppressing plasma concentrations of mTARC, histamine and IgE. Copyright © 2011 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here